Search

Search Constraints

You searched for: Author/Creator Clayton, David

Search Results

2. Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. Issue 4 (October 2019)

3. The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort. Issue 1 (8th March 2018)

4. F4‐04‐04: ASSOCIATION BETWEEN CEREBRAL AMYLOIDOSIS AND WORSE COGNITIVE PERFORMANCE IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: BASELINE FINDINGS FROM THE API COLOMBIA AUTOSOMAL DOMINANT AD TRIAL. (1st July 2019)

5. F4‐04‐03: RELATIONSHIPS BETWEEN BASELINE BRAIN IMAGING BIOMARKER MEASUREMENTS AND AGE IN THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL. (1st July 2019)

6. O4‐11‐06: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE. (1st July 2014)

8. Sex differences in neurodegeneration and memory performance in preclinical autosomal dominant Alzheimer's disease: Baseline findings from the API ADAD trial: Intersections of sex/gender and race/ethnicity in cognitive aging and Alzheimer's disease trajectories. (7th December 2020)

9. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease: Neuroimaging / imaging and genetics. (7th December 2020)

10. Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis. Issue 7 (15th January 2019)